Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has licensed rights to a panel of cancer therapeutic antibodies to Peptech Limited.
CRT has granted Peptech an exclusive worldwide licence to a panel of cancer therapeutic antibodies for therapeutic, vaccine and in vitro diagnostic use. The antibodies were originally licensed by CRT to UK biotechnology company Scancell Limited (Scancell), who selected two preclinical lead antibodies, SC101 and SC104 for development in colorectal cancer. Peptech has acquired the entire panel of cancer therapeutic antibodies and the intellectual property relating to these programmes from both Scancell and CRT. Scancell is now using the revenue to progress its novel cancer vaccine platform that it co-developed with CRT.
The panel of antibodies was originally developed by Cancer Research UK-funded studies led by Professor Lindy Durrant at the University of Nottingham and targets antigens that are over-expressed on a variety of tumours. SC101 is a mouse monoclonal antibody recognising Lewis y/b.